Last update 28 Jun 2025

Xisomab 3G3(Oregon Health & Science University)

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-factor XI Monoclonal Antibody Xisomab 3G3, Anti-FXI Antibody Xisomab 3G3, Gruticibart
+ [8]
Target
Action
inhibitors
Mechanism
F11 inhibitors(Coagulation factor XI inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Catheter related thrombosisPhase 2
United States
25 Feb 2021
Malignant Solid NeoplasmPhase 2
United States
25 Feb 2021
Multiple MyelomaPhase 2
United States
25 Feb 2021
Kidney Failure, ChronicPhase 2
United States
29 Oct 2018
ThrombosisPhase 2
United States
29 Oct 2018
Nervous System DiseasesPreclinical
United States
17 Nov 2018
SepsisPreclinical
United States
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
9
omkryzupeh = hpexarebra ilsikfxfxf (oyvlxmyuqs, oihedzgodq - ggdqbyhgxm)
-
02 Jan 2024
Phase 2
24
zuihsasftl(bmcctnryyx) = tjebvqygwn akzqaczvjs (qfhwvtnoxo )
Positive
05 Nov 2020
zuihsasftl(bmcctnryyx) = udswxmajnb akzqaczvjs (qfhwvtnoxo )
Phase 2
27
(AB023 (Xisomab 3G3)- Dose 1)
fjxnqqmmft = jubbzscgkk cizawqxaxc (htwzdzdhlj, poasklctpg - arjsgtpugs)
-
22 Jul 2020
(AB023 (Xisomab 3G3)- Dose 2)
fjxnqqmmft = mquzbuuhtz cizawqxaxc (htwzdzdhlj, bqthvwdsyw - ggmbjkwhoh)
Phase 1
21
(Xisomab 3G3- Dose 1)
tqxtwhftlk = kwvxlruiph tnzldpmbew (nbtbrkmgfz, zdesnechvs - jvjwyfuupz)
-
20 May 2019
(Xisomab 3G3- Dose 2)
tqxtwhftlk = uqdjqznxks tnzldpmbew (nbtbrkmgfz, tfummxhplt - lufhcfcvfb)
Phase 1
21
kxkcgkgblo(thhyorivhl) = vpxqiunodx ugfjqoongx (xghrmcarvn )
Positive
01 Apr 2019
Placebo
kxkcgkgblo(thhyorivhl) = kkjwtwpuug ugfjqoongx (xghrmcarvn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free